interleukin 6 il 6 inhibitors therapeutics n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
IL-6 Inhibitors Therapeutics - Pipeline Review 2017 PowerPoint Presentation
Download Presentation
IL-6 Inhibitors Therapeutics - Pipeline Review 2017

Loading in 2 Seconds...

play fullscreen
1 / 7

IL-6 Inhibitors Therapeutics - Pipeline Review 2017 - PowerPoint PPT Presentation


  • 1 Views
  • Uploaded on

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'IL-6 Inhibitors Therapeutics - Pipeline Review 2017' - psmarket


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
interleukin 6 il 6 inhibitors therapeutics

Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline to Witness Many Collaborations in Coming Years

interleukin 6 il 6 inhibitors therapeutics 1

Interleukin-6 (IL-6) Inhibitors Therapeutics

IL-6 inhibitors therapeutics pipeline in 2017

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.

interleukin 6 il 6 inhibitors therapeutics 2

Interleukin-6 (IL-6) Inhibitors Therapeutics

Insights on pipeline segments

According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.

Access Report Summary with Detailed TOC on "Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/interleukin-6-inhibitors-therapeutics-pipeline

interleukin 6 il 6 inhibitors therapeutics 3

Interleukin-6 (IL-6) Inhibitors Therapeutics

Positive Clinical Results of IL-6 Inhibitors Therapeutics Candidates

The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.

interleukin 6 il 6 inhibitors therapeutics 4

Interleukin-6 (IL-6) Inhibitors Therapeutics

Various collaborations for IL-6 Inhibitors therapeutics drug development

In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.

interleukin 6 il 6 inhibitors therapeutics 5

Interleukin-6 (IL-6) Inhibitors Therapeutics

Download report sample at:

https://www.psmarketresearch.com/market-analysis/interleukin-6-inhibitors-therapeutics-pipeline/report-sample

get in touch

GET IN TOUCH

THANK YOU!

For information regarding permissions and other queries

Kindly write to:

US/Canada Toll-Free: 1-888-778-7886